At a glance
ClinicalIndex Comparison RecordN/ACompleted· 286 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus (ADVN AMP01)
National Institute of Allergy and Infectious Diseases (NIAID)·observational·Posted Dec 4, 2006·Updated Oct 18, 2016
In Brief
An observational study for Atopic Dermatitis. Completed, enrolled 286 participants across 1 site.
Detailed Summary
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by recurrent viral skin infections. Recent studies have demonstrated that the skin of people with AD my have decreased antimicrobial peptide (AMP) expression. The purpose of this study is to compare smallpox virus replication and the number of AMPs and other antiviral molecules in people with AD, as compared to those seen in people with psoriasis or asthma, or healthy individuals.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2005
First PostedDec 2006
Primary CompletionFeb 2010
TodayJul 2026
First PostedDec 4, 2006
Enrollment StartJun 1, 2005
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 19.6 years ago